Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

ZIMMER BIOMET HOLDINGS, INC. (ZBH)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $101.41 (close 2026-11-16); latest close $101.10 (2026-11-20), -0.3% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case +1% · downside -23% · upside +10%

At $101.41 the market is not paying for growth: 25.0x TTM earnings, near the five-year median of 25.3x, while the reverse DCF prices -8.0% annual revenue for a decade. Cash generation is attractive, with an 8.6% FCF yield and 4.32% net buyback yield, but ROIC of 5.0% sits below the 5.4% WACC, so the evidence supports a low-conviction PASS rather than a directional bet. The downside is -23.5% to $77.58 on -10.0% earnings at a compressed P/E of 21.25x (today 25.0x). The base is +0.8% to $102.22 with P/E at 25.2x, the peer median P/E across five peers. The upside is +10.0% to $111.55 on +10% earnings at today's P/E of 25x. Those outcomes frame a balanced range around today's price, leaving no strong edge.

Key numbers

  • Share price: $101.10
  • Market cap: $19.13B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $8.57B
  • EV / EBITDA (TTM): 11.6x
  • P/E (TTM): 24.9x
  • FCF yield: 8.6%
  • Price / book: 1.51x
  • Earnings-quality flags (TTM): none flagged
  • EV / FCF (TTM): 16.0x
  • Revenue growth (latest fiscal year): +7.2%
  • ROIC (TTM): 5.0%
  • WACC: 5.4%
  • Economic profit spread: -0.4 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Zimmer Biomet makes money selling orthopedic reconstructive, S.E.T., CMFT, bone cement, surgical and digital/robotic products, mainly through direct hospital/ASC accounts and distributors/dealers, with about 85% of 2025 net sales on consignment. The latest 10-K runs the business through Americas, EMEA and Asia Pacific; the U.S. is about 95% of Americas net sales and Japan about 50% of Asia Pacific. Revenue and operating income rose from $6.13B and $83.1M in FY2020 to $8.57B and $1.16B TTM to 2026-09-30; TTM operating cash flow was $1.88B, and TTM D&A was $1.11B including $669.2M of intangible amortization.

  2. ✓ 2. Competitive advantage

    The sources name three scaled rivals — J&J MedTech (ex-DePuy Synthes), Stryker and Smith & Nephew — and put pricing on the same footing as technology, quality and reputation, so no pricing-power moat is documented. What the numbers show is scale and process, not a wide moat: revenue rose every year in the six-year table from $6.13B (FY2020) to $8.23B (FY2025) and $8.57B TTM, while operating income ran $83.1M in FY2020, $1.10B in FY2025 and $1.16B TTM, roughly 13% of revenue in the latest periods. The cash economics look better than the reported margin because intangible amortization ($665.9M FY2025, $669.2M TTM) and total D&A ($1.09B, $1.11B) absorb nearly all operating income, while capex is only $224.5M against $1.70B of operating cash flow in FY2025. Book returns stay low because $9.9B of goodwill and $4.7B of intangibles sit against $12.70B of total equity.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 net sales were $2,062.9 million, up 3.1% reported and 3.7% constant currency, with volume/mix +4.4%, pricing -0.7% and FX -0.6%; nine-month 2026 sales were $6,326.6 million, up 5.7% reported, 5.0% constant currency and 3.5% organic constant currency. Q3 2026 operating margin compressed to 14.9% from 17.6%, and net earnings fell to $191.6 million from $230.9 million largely on prior-year $55.1 million contingent-consideration adjustments, while adjusted diluted EPS was $1.90, flat year over year. Cash was $399.9 million at September 30, 2026, nine-month 2026 operating cash flow was $1,367.2 million, and nine-month buybacks were $579.3 million; FY2026 guidance was raised to 4.4%-4.9% reported revenue growth and $8.50-$8.60 adjusted diluted EPS. The 10-Q risk-factor section points back to the 2025 Form 10-K, while the computed 10-K diff shows 22 paragraphs with no counterpart in the prior report.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans